T1	Participants 291 342	65 children who received one round of DMSA (3 days)
T2	Participants 457 580	49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo
T3	Participants 210 264	children with autism spectrum disorders ages 3-8 years
